Galectin Competitors
| GALT Stock | USD 1.15 0.28 32.18% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Galectin Therapeutics competition on your existing holdings.
Galectin |
Galectin Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Galectin Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Galectin and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Galectin Therapeutics does not affect the price movement of the other competitor.
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Galectin Stock performing well and Galectin Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Galectin Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| MDGL | 2.58 | 0.62 | 0.26 | 0.65 | 1.96 | 5.17 | 30.27 | |||
| VKTX | 3.23 | (0.55) | 0.00 | (0.72) | 0.00 | 5.82 | 39.28 | |||
| SRPT | 1.82 | (0.02) | 0.00 | (0.03) | 0.00 | 3.75 | 18.21 | |||
| HEPA | 3.71 | (0.47) | 0.00 | 1.05 | 0.00 | 8.06 | 35.17 | |||
| PTCT | 2.86 | 0.38 | 0.14 | 0.87 | 2.35 | 7.02 | 23.95 | |||
| ICPT | 2.96 | (0.77) | 0.00 | 1.42 | 0.00 | 5.23 | 38.17 | |||
| TERN | 3.04 | (0.65) | 0.00 | (1.53) | 0.00 | 5.17 | 26.61 | |||
| AKRO | 2.64 | 0.05 | 0.01 | 0.34 | 3.12 | 5.23 | 13.97 | |||
| RETA | 2.22 | 0.21 | 0.05 | (0.32) | 3.31 | 5.24 | 28.80 | |||
| DMAC | 3.34 | 0.53 | 0.13 | 2.38 | 3.49 | 8.64 | 47.69 |
Cross Equities Net Income Analysis
Compare Galectin Therapeutics and related stocks such as Madrigal Pharmaceuticals, Viking Therapeutics, and Sarepta Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDGL | (381 K) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (68.7 M) | (26.4 M) | (31.2 M) | (32.8 M) | (72.8 M) | (197.4 M) | (241.1 M) | (299.3 M) | (373.6 M) | (354.9 M) |
| SRPT | (2.6 M) | (2.3 M) | (121.3 M) | (112 M) | (135.8 M) | (220 M) | (267.3 M) | (50.7 M) | (361.9 M) | (715.1 M) | (554.1 M) | (418.8 M) | (703.5 M) | (536 M) | (509.2 M) |
| HEPA | (843 K) | (843 K) | (843 K) | (5.3 M) | (5.3 M) | (14.3 M) | (17 M) | (14.9 M) | (9.4 M) | (7 M) | (20.4 M) | (32.7 M) | (42.2 M) | (48.9 M) | (46.5 M) |
| PTCT | 30.9 M | 30.9 M | (26.2 M) | (51.6 M) | (93.8 M) | (170.4 M) | (142.1 M) | (79 M) | (128.1 M) | (251.6 M) | (438.2 M) | (523.9 M) | (559 M) | (626.6 M) | (595.3 M) |
| TERN | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (68.8 M) | (40.6 M) | (50.2 M) | (60.3 M) | (90.2 M) | (85.7 M) |
| AKRO | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (81.7 M) | (43.8 M) | (79.2 M) | (100.7 M) | (108.9 M) | (151.8 M) | (144.2 M) |
| DMAC | (640 K) | (6.6 M) | (10.1 M) | (7.4 M) | (4.8 M) | (1.4 M) | (2.2 M) | (4.3 M) | (5.7 M) | (10.6 M) | (12.3 M) | (13.6 M) | (13.7 M) | (19.4 M) | (18.4 M) |
| MIST | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (23.2 M) | (55.2 M) | (50 M) | (42.6 M) | (57.1 M) | (59.7 M) | (62.7 M) |
| MCRB | (3.1 M) | (3.1 M) | (3.1 M) | (6.1 M) | (16.7 M) | (54.8 M) | (91.6 M) | (89.4 M) | (98.9 M) | (64.2 M) | (86.5 M) | (61.5 M) | (253.8 M) | (113.7 M) | (119.4 M) |
| IKT | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (5.7 M) | (2.9 M) | (14.8 M) | (17.9 M) | (19 M) | (18.1 M) |
| ONCY | (574.5 K) | (29 M) | (36.4 M) | (23.5 M) | (18.6 M) | (13.7 M) | (15.1 M) | (15.6 M) | (17 M) | (45.6 M) | (19.6 M) | (26.3 M) | (24.8 M) | (27.8 M) | (29.1 M) |
| ETNB | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (57.4 M) | (49.5 M) | (90.1 M) | (102 M) | (142.2 M) | (135.1 M) |
| PLRX | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | 185 K | (39.7 M) | (17.9 M) | (121.5 M) | (161.3 M) | (153.3 M) |
| ACLX | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (32.1 M) | (63.9 M) | (186.1 M) | (70.7 M) | (74.2 M) |
| STOK | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (12.5 M) | (28.5 M) | (50.6 M) | (84.7 M) | (93.1 M) | (104.7 M) | (99.5 M) |
Galectin Therapeutics and related stocks such as Madrigal Pharmaceuticals, Viking Therapeutics, and Sarepta Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Galectin Therapeutics financial statement analysis. It represents the amount of money remaining after all of Galectin Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Galectin Therapeutics Competitive Analysis
The better you understand Galectin Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Galectin Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Galectin Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Galectin Therapeutics Competition Performance Charts
Five steps to successful analysis of Galectin Therapeutics Competition
Galectin Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Galectin Therapeutics in relation to its competition. Galectin Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Galectin Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Galectin Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Galectin Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Galectin Therapeutics position
In addition to having Galectin Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Silver Thematic Idea Now
Silver
Companies involved in mining, production, and distribution of silver and silver goods. The Silver theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Silver Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.